April 25, 2025
Caribou CEO Rachel Haurwitz.
Elizabeth D. Herman for STAT

STAT+ | Caribou delays readout, discontinues programs, betting on off-the-shelf CAR-T therapies

The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood cancer.

By Adam Feuerstein


STAT+ | NIH grants plummeted $2.3 billion in Trump’s first months, as federal-academia partnership crumbles

As Trump administration nears its 100th day, the partnership that has been propelling American biomedical innovation is imperiled

By Megan Molteni, J. Emory Parker, and Jonathan Wosen


STAT+ | Women’s Health Initiative, known for hormone therapy trials, to lose federal funding

The WHI, an enormous study that shaped treatment of menopause symptoms and other conditions, is on the verge of shutting down

By Elizabeth Cooney



President Trump signs a memorandum in the Oval Office of the White House on Jan. 30.
Chip Somodevilla/Getty Images

Day by day, how Trump is roiling science and health

This timeline of the Trump administration documents decisions and events that have transpired with unprecedented speed since his inauguration

By Usha Lee McFarling


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.